Singapore-headquartered Tessa Therapeutics, a clinical stage biopharmaceutical company focusing on cellular immunotherapy treatments for solid tumors, announced recently the appointment of Desmond Lim as CFO.
Lim joins Tessa from Heptagon, a developer and manufacturer of advanced micro-optics based solutions and systems, where he was the CFO and successfully took the company through a strategic acquisition process by a European listed conglomerate.
Lim has more than 25 years of finance experience and has held multiple senior executive roles in the recent decade.
He started his career in auditing with Arthur Andersen & Co in Australia, followed by treasury and capital markets roles at Deutsche Bank and at GE Capital. Desmond worked as Vice President and Asia Pacific Chief Financial Officer at Honeywell International and as Global Treasurer at Avago Technologies (now Broadcom).